Lilly's Foundayo demonstrated cardiovascular safety, sustained A1c reduction and weight loss

LLY•2026-09-30

In its largest and longest type 2 diabetes study, Lilly's Foundayo showed cardiovascular safety alongside sustained A1c reduction and weight loss, with lower reported death and MACE risks than insulin glargine.

Lilly's Foundayo demonstrated cardiovascular safety, sustained A1c reduction and weight loss

1. Study results

Related News

TTM Technologies completes acquisition of Epiq Solutions, enhancing its strategic A&D portfolio

Osisko Gold completes US$600 million offering of 9.250% senior secured notes

MSG Sports board approves spin-off of Rangers business from Knicks business

Reed’s refinances $9.25 million senior secured credit facility, strengthens balance sheet

Mackenzie Realty Capital board temporarily suspends preferred share repurchase program